CYLD - a deubiquitylase that acts to fine-tune microtubule properties and functions

Journal of Cell Science

Volumn 129, Issue 12, 2016, Pages 2289-2295

  Yang, Yunfan ^a   Zhou, Jun ^a,b  

^a NANKAI UNIVERSITY   (China)

^b SHANDONG NORMAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cell migration; Ciliogenesis; CYLD; Drug sensitivity; Microtubule

Indexed keywords

CYCLOHEXIMIDE; CYLINDROMATOSIS PROTEIN; NOSCAPINE; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE; DEUBIQUITINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE PROGRESSION; CELL MIGRATION; CILIARY MOTILITY; CILIOGENESIS; CYTOKINESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; KINETOSOME; MICROTUBULE; MICROTUBULE ASSEMBLY; NONHUMAN; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; CELL MOTION; CILIUM; METABOLISM;

ANIMALS; CELL CYCLE; CELL MOVEMENT; CILIA; HUMANS; MICROTUBULES; MODELS, BIOLOGICAL; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84976486955     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.183319     Document Type: Note

References (69)

1. Bauer, J. A., Chakravarthy, A. B., Rosenbluth, J. M., Mi, D., Seeley, E. H., De Matos Granja-Ingram, N., Olivares, M. G., Kelley, M. C., Mayer, I. A., Meszoely, I. M. et al. (2010). Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res. 16, 681-690.
2. Bignell, G. R., Warren, W., Seal, S., Takahashi, M., Rapley, E., Barfoot, R., Green, H., Brown, C., Biggs, P. J., Lakhani, S. R. et al. (2000). Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160-165.
3. Brummelkamp, T. R., Nijman, S. M. B., Dirac, A. M. G. and Bernards, R. (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797-801.
4. Chen, Y.,Wang, Z.,Wang, P., Li, D., Zhou, J. and Wu, S. (2014). CYLD negatively regulates Hippo signaling by limiting Hpo phosphorylation in Drosophila. Biochem. Biophys. Res. Commun. 452, 808-812.
5. Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelieres, F. P., King, S. J., Humbert, S. and Saudou, F. (2007). Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571-3583.
6. Dosemeci, A., Thein, S., Yang, Y., Reese, T. S. and Tao-Cheng, J.-H. (2013). CYLD, a deubiquitinase specific for lysine63-linked polyubiquitins, accumulates at the postsynaptic density in an activity-dependent manner. Biochem. Biophys. Res. Commun. 430, 245-249.
7. Dumontet, C. and Jordan, M. A. (2010). Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790-803.
8. Eguether, T., Ermolaeva, M. A., Zhao, Y., Bonnet, M. C., Jain, A., Pasparakis, M., Courtois,G. andTassin,A.-M. (2014). The deubiquitinating enzymeCYLDcontrols apical docking of basal bodies in ciliated epithelial cells. Nat. Commun. 5, 4585.
9. Etienne-Manneville, S. (2010). From signaling pathways to microtubule dynamics: the key players. Curr. Opin. Cell Biol. 22, 104-111.
10. Gao, J., Huo, L., Sun, X., Liu, M., Li, D., Dong, J.-T. and Zhou, J. (2008). The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J. Biol. Chem. 283, 8802-8809.
11. Gao, J., Sun, L., Huo, L., Liu, M., Li, D. and Zhou, J. (2010). CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 115, 4130-4137.
12. Gomez-Ferreria, M. A., Bashkurov, M., Mullin, M., Gingras, A.-C. and Pelletier, L. (2012). CEP192 interacts physically and functionally with the K63-deubiquitinase CYLD to promote mitotic spindle assembly. Cell Cycle 11, 3555-3558.
13. Gouveia, S. M. and Akhmanova, A. (2010). Cell and molecular biology of microtubule plus end tracking proteins: end binding proteins and their partners. Int. Rev. Cell Mol. Biol. 285, 1-74.
14. Hellerbrand, C. and Massoumi, R. (2016). Cylindromatosis-a protective molecule against liver diseases. Med. Res. Rev. 36, 342-359.
15. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F. and Yao, T.-P. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458.
16. Ishikawa, Y., Tsunoda, K., Shibazaki, M., Takahashi, K., Akasaka, T., Masuda, T. and Maesawa, C. (2012). Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity. Int. J. Oncol. 41, 53-60.
17. Jin, W., Chang, M., Paul, E. M., Babu, G., Lee, A. J., Reiley,W.,Wright, A., Zhang, M., You, J. and Sun, S. C. (2008). Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 118, 1858-1866.
18. Kaul, N., Soppina, V. and Verhey, K. J. (2014). Effects of alpha-tubulin K40 acetylation and detyrosination on kinesin-1 motility in a purified system. Biophys. J. 106, 2636-2643.
19. Ke, H., Augustine, C. K., Gandham, V. D., Jin, J. Y., Tyler, D. S., Akiyama, S. K., Hall, R. P. and Zhang, J. Y. (2013). CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and beta1-integrin signaling pathways. J. Invest. Dermatol. 133, 221-229.
20. Komander, D. and Rape, M. (2012). The ubiquitin code. Annu. Rev. Biochem. 81, 203-229.
21. Komander, D., Lord, C. J., Scheel, H., Swift, S., Hofmann, K., Ashworth, A. and Barford, D. (2008). The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol. Cell 29, 451-464.
22. Komander, D., Reyes-Turcu, F., Licchesi, J. D. F., Odenwaelder, P., Wilkinson, K. D. and Barford, D. (2009). Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473.
23. Li, D., Gao, J., Yang, Y., Sun, L., Suo, S., Luo, Y., Shui, W., Zhou, J. and Liu, M. (2014). CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration. Cell Cycle 13, 974-983.
24. Liang, G., Ahlqvist, K., Pannem, R., Posern, G. and Massoumi, R. (2011). Serum response factor controls CYLD expression via MAPK signaling pathway. PLoS ONE 6, e19613.
25. Lim, J. H., Stirling, B., Derry, J., Koga, T., Jono, H., Woo, C.-H., Xu, H., Bourne, P., Ha, U.-H., Ishinaga, H. et al. (2007). Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27, 349-360.
26. Lim, J. H., Jono, H., Komatsu, K., Woo, C.-H., Lee, J., Miyata, M., Matsuno, T., Xu, X., Huang, Y., Zhang, W. et al. (2012). CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat. Commun. 3, 771.
27. Liu, N., Xiong, Y., Li, S., Ren, Y., He, Q., Gao, S., Zhou, J. and Shui, W. (2015). New HDAC6-mediated deacetylation sites of tubulin in the mouse brain identified by quantitative mass spectrometry. Sci. Rep. 5, 16869.
28. Luo, Y., Li, D., Ran, J., Yan, B., Chen, J., Dong, X., Liu, Z., Liu, R., Zhou, J. and Liu, M. (2014). End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability. Protein Cell 5, 469-479.
29. Malik, S. (2014). Polydactyly: phenotypes, genetics and classification. Clin. Genet. 85, 203-212.
30. Massoumi, R. (2010). Ubiquitin chain cleavage: CYLD at work. Trends Biochem. Sci. 35, 392-399.
31. Massoumi, R. (2011). CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncol. 7, 285-297.
32. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A. and Fässler, R. (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125, 665-677.
33. Massoumi, R., Kuphal, S., Hellerbrand, C., Haas, B.,Wild, P., Spruss, T., Pfeifer, A., Fässler, R. and Bosserhoff, A. K. (2009). Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 206, 221-232.
34. Mathis, B. J., Lai, Y., Qu, C., Janicki, J. S. and Cui, T. (2015). CYLD-mediated signaling and diseases. Curr. Drug Targets 16, 284-294.
35. Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin-Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S. et al. (2002). In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21, 6820-6831.
36. Miliani de Marval, P., Lutfeali, S., Jin, J. Y., Leshin, B., Selim, M. A. and Zhang, J. Y. (2011). CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer Prev. Res. 4, 851-859.
37. Mohan, R., Katrukha, E. A., Doodhi, H., Smal, I., Meijering, E., Kapitein, L. C., Steinmetz, M. O. and Akhmanova, A. (2013). End-binding proteins sensitize microtubules to the action of microtubule-targeting agents. Proc. Natl. Acad. Sci. USA 110, 8900-8905.
38. Nikolaou, K., Tsagaratou, A., Eftychi, C., Kollias, G., Mosialos, G. and Talianidis, I. (2012). Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 21, 738-750.
39. Rajan, N., Elliott, R. J. R., Smith, A., Sinclair, N., Swift, S., Lord, C. J. and Ashworth, A. (2014). The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling. Oncotarget 5, 12126-12140.
40. Ran, J., Yang, Y., Li, D., Liu, M. and Zhou, J. (2015). Deacetylation of alpha-tubulin and cortactin is required forHDAC6to trigger ciliary disassembly. Sci.Rep. 5, 12917.
41. Reed, N. A., Cai, D., Blasius, T. L., Jih, G. T., Meyhofer, E., Gaertig, J. and Verhey, K. J. (2006). Microtubule acetylation promotes kinesin-1 binding and transport. Curr. Biol. 16, 2166-2172.
42. Reiley,W. W., Zhang, M., Jin, W., Losiewicz, M., Donohue, K. B., Norbury, C. C. and Sun, S.-C. (2006). Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 7, 411-417.
43. Rida, P. C. G., LiVecche, D., Ogden, A., Zhou, J. and Aneja, R. (2015). The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications. Med. Res. Rev. 35, 1072-1096.
44. Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A. et al. (2005). Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. USA 102, 8315-8320.
45. Sato, Y., Goto, E., Shibata, Y., Kubota, Y., Yamagata, A., Goto-Ito, S., Kubota, K., Inoue, J.-i., Takekawa, M., Tokunaga, F. et al. (2015). Structures of CYLD USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity. Nat. Struct. Mol. Biol. 22, 222-229.
46. Stegmeier, F., Sowa, M. E., Nalepa, G., Gygi, S. P., Harper, J. W. and Elledge, S. J. (2007). The tumor suppressor CYLD regulates entry into mitosis. Proc. Natl. Acad. Sci. USA 104, 8869-8874.
47. Steinmetz, M. O. and Akhmanova, A. (2008). Capturing protein tails by CAP-Gly domains. Trends Biochem. Sci. 33, 535-545.
48. Sun, S.-C. (2010). CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17, 25-34.
49. Sun, L., Gao, J., Huo, L., Sun, X., Shi, X., Liu, M., Li, D., Zhang, C. and Zhou, J. (2010). Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. J. Pathol. 221, 425-432.
50. Sun, X., Li, D., Yang, Y., Ren, Y., Li, J., Wang, Z., Dong, B., Liu, M. and Zhou, J. (2012). Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J. Pathol. 226, 666-673.
51. Thein, S., Pham, A., Bayer, K. U., Tao-Cheng, J.-H. and Dosemeci, A. (2014a). IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem. Biophys. Res. Commun. 450, 550-554.
52. Thein, S., Tao-Cheng, J.-H., Li, Y., Bayer, K. U., Reese, T. S. and Dosemeci, A. (2014b). CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS ONE 9, e91312.
53. Trompouki, E., Tsagaratou, A., Kosmidis, S. K., Dollé, P., Qian, J., Kontoyiannis, D. L., Cardoso, W. V. and Mosialos, G. (2009). Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11, 469-476.
54. Urbe, S., Liu, H., Hayes, S. D., Heride, C., Rigden, D. J. and Clague, M. J. (2012). Systematic survey of deubiquitinase localization identifies USP21 as a regulator of centrosome- and microtubule-associated functions. Mol. Biol. Cell 23, 1095-1103.
55. Walter, W. J., Beránek, V., Fischermeier, E. and Diez, S. (2012). Tubulin acetylation alone does not affect kinesin-1 velocity and run length in vitro. PLoS ONE 7, e42218.
56. Wang, H., Liu, B., Zhang, C., Peng, G., Liu, M., Li, D., Gu, F., Chen, Q., Dong, J.-T., Fu, L. et al. (2009). Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism. J. Pathol. 218, 76-85.
57. Weisbrich, A., Honnappa, S., Jaussi, R., Okhrimenko, O., Frey, D., Jelesarov, I., Akhmanova, A. and Steinmetz, M. O. (2007). Structure-function relationship of CAP-Gly domains. Nat. Struct. Mol. Biol. 14, 959-967.
58. Welte, S., Urbanik, T., Elssner, C., Kautz, N., Koehler, B. C., Waldburger, N., Bermejo, J. L., Pinna, F., Weiss, K.-H., Schemmer, P. et al. (2014). Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. PLoS ONE 9, e110591.
59. Wickström, S. A., Masoumi, K. C., Khochbin, S., Fässler, R. and Massoumi, R. (2010). CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J. 29, 131-144.
60. Wright, A., Reiley,W.W., Chang, M., Jin,W., Lee, A. J., Zhang, M. and Sun, S.-C. (2007). Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev. Cell 13, 705-716.
61. Xie, S., Ogden, A., Aneja, R. and Zhou, J. (2016). Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy. Med. Res. Rev. 36, 300-312.
62. Yang, Y., Sun, L., Tala, L., Gao, J., Li, D., Zhou, J. and Liu, M. (2013). CYLD regulates RhoA activity by modulating LARG ubiquitination. PLoS ONE 8, e55833.
63. Yang, Y., Liu, M., Li, D., Ran, J., Gao, J., Suo, S., Sun, S.-C. and Zhou, J. (2014a). CYLD regulates spindle orientation by stabilizing astral microtubules and promoting dishevelled-NuMA-dynein/dynactin complex formation. Proc. Natl. Acad. Sci. USA 111, 2158-2163.
64. Yang, Y., Ran, J., Liu, M., Li, D., Li, Y., Shi, X., Meng, D., Pan, J., Ou, G., Aneja, R. et al. (2014b). CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6. Cell Res. 24, 1342-1353.
65. Yang, Y., Ran, J., Sun, L., Sun, X., Luo, Y., Yan, B., Tala, B., Liu, M., Li, D., Zhang, L. et al. (2015). CYLD regulates noscapine activity in acute lymphoblastic leukemia via a microtubule-dependent mechanism. Theranostics 5, 656-666.
66. Yu, F., Ran, J. and Zhou, J. (2016). Ciliopathies: does HDAC6 represent a new therapeutic target? Trends Pharmacol. Sci. 37, 114-119.
67. Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S. and Matthias, P. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22, 1168-1179.
68. Zhang, J., Stirling, B., Temmerman, S. T., Ma, C. A., Fuss, I. J., Derry, J.M. J. and Jain, A. (2006). Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116, 3042-3049.
69. Zhao, Y., Thornton, A. M., Kinney, M. C., Ma, C. A., Spinner, J. J., Fuss, I. J., Shevach, E. M. and Jain, A. (2011). The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor beta (TGF-beta) signaling and the development of regulatory T cells. J. Biol. Chem. 286, 40520-40530.